Genetic Concepts, LLC

genetic-concepts.com

You owe it to yourself to be with the best in the business so that you can be the best in your market! Genetic Concepts is a leading lab distribution company with well compensated representatives specializing in Molecular Testing, Toxicology Testing and Compounding Pharmacy. So, how does your pharmacy compare to ours? Do they provide you true transparency with an online portal containing real time data on the status of all your scripts and payouts?

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

KUBOTA VISION ANNOUNCES COLLABORATION AGREEMENT WITH LEADING DIABETES CENTER

PBOS | September 30, 2022

news image

Kubota Vision Inc. a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. announced today that the Company and Joslin Diabetes Center have entered into a material transfer and collaboration agreement for our Patient Based Ophthalmology Suite in-home optical coherence tomography device. Joslin Diabetes Center is conducting two clinical studies to evaluate the ability of PBOS to identify cases of diabetic macular ed...

Read More

PFIZER LAYS OUT GENE THERAPY ASPIRATIONS

BioPharma Dive | January 28, 2020

news image

Pfizer aims to be the third big pharma with a significant presence in gene therapy. Its plans to initiate this year three Phase 3 trials targeting mutation-driven blood and muscular diseases would make it a large player in this cutting-edge area of medicine. The difference between Pfizer and its Swiss rivals Novartis and Roche is that its treatments for muscular dystrophy and hemophilia do not look like they will be the first to market. With hopes that gene therapy could be a one-and-done treatm...

Read More

Pharma Tech

INNATE PHARMA TO PRESENT LACUTAMAB PTCL PHASE 1B DESIGN AND ANKET™ PLATFORM AT ESMO 2022

Innate Pharma | September 06, 2022

news image

Innate Pharma SA announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. About Lacutamab Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma an orphan disease, and peripheral T cell lymphoma. Rare cutaneous lymphomas of T lymphocytes has a poor prognos...

Read More

Pharmacy Market

MEDISCA CHOOSES CREATIO TO SPEED UP OPERATIONS AND INCREASE MARKET SHARE

MEDISCA | June 18, 2021

news image

MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee. MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company...

Read More
news image

Business Insights

KUBOTA VISION ANNOUNCES COLLABORATION AGREEMENT WITH LEADING DIABETES CENTER

PBOS | September 30, 2022

Kubota Vision Inc. a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. announced today that the Company and Joslin Diabetes Center have entered into a material transfer and collaboration agreement for our Patient Based Ophthalmology Suite in-home optical coherence tomography device. Joslin Diabetes Center is conducting two clinical studies to evaluate the ability of PBOS to identify cases of diabetic macular ed...

Read More
news image

PFIZER LAYS OUT GENE THERAPY ASPIRATIONS

BioPharma Dive | January 28, 2020

Pfizer aims to be the third big pharma with a significant presence in gene therapy. Its plans to initiate this year three Phase 3 trials targeting mutation-driven blood and muscular diseases would make it a large player in this cutting-edge area of medicine. The difference between Pfizer and its Swiss rivals Novartis and Roche is that its treatments for muscular dystrophy and hemophilia do not look like they will be the first to market. With hopes that gene therapy could be a one-and-done treatm...

Read More
news image

Pharma Tech

INNATE PHARMA TO PRESENT LACUTAMAB PTCL PHASE 1B DESIGN AND ANKET™ PLATFORM AT ESMO 2022

Innate Pharma | September 06, 2022

Innate Pharma SA announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. About Lacutamab Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma an orphan disease, and peripheral T cell lymphoma. Rare cutaneous lymphomas of T lymphocytes has a poor prognos...

Read More
news image

Pharmacy Market

MEDISCA CHOOSES CREATIO TO SPEED UP OPERATIONS AND INCREASE MARKET SHARE

MEDISCA | June 18, 2021

MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee. MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us